

Andrea N Edginton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6708971/publications.pdf>

Version: 2024-02-01

58
papers

1,969
citations

279701

23
h-index

254106

43
g-index

59
all docs

59
docs citations

59
times ranked

1939
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2022, 61, 307-320.	1.6	13
2	Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature. <i>Clinical Pharmacokinetics</i> , 2022, 61, 189-229.	1.6	7
3	Development and Evaluation of an In Silico Dermal Absorption Model Relevant for Children. <i>Pharmaceutics</i> , 2022, 14, 172.	2.0	4
4	Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies. <i>Pharmaceutical Research</i> , 2022, 39, 239.	1.7	2
5	Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis. <i>Pharmaceutics</i> , 2022, 14, 356.	2.0	0
6	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. <i>HemaSphere</i> , 2022, 6, e694.	1.2	1
7	A Mechanistic Bayesian Inferential Workflow for Estimation of In Vivo Skin Permeation from In Vitro Measurements. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 838-851.	1.6	4
8	Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2022, 61, 997-1012.	1.6	2
9	Use of physiologically based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 778-791.	1.3	5
10	Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence. <i>Frontiers in Pediatrics</i> , 2022, 10, .	0.9	4
11	Physiologically Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 253-262.	2.3	27
12	Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. <i>Haemophilia</i> , 2021, 27, 358-365.	1.0	9
13	Incorporating Breastfeeding-Related Variability with Physiologically Based Pharmacokinetic Modeling to Predict Infant Exposure to Maternal Medication Through Breast Milk: a Workflow Applied to Lamotrigine. <i>AAPS Journal</i> , 2021, 23, 70.	2.2	5
14	Assessment of Vehicle Volatility and Deposition Layer Thickness in Skin Penetration Models. <i>Pharmaceutics</i> , 2021, 13, 807.	2.0	9
15	Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1896-1906.	1.9	12
16	Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. <i>Drug Metabolism and Disposition</i> , 2021, 49, 844-855.	1.7	4
17	Pediatric Dose Selection for Therapeutic Proteins. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S193-S206.	1.0	9
18	External qualification of the Web-Accessible Population Pharmacokinetic Service "Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12599.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. <i>Clinical Pharmacokinetics</i> , 2020, 59, 245-256.	1.6	18
20	Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 466-476.	1.0	21
21	Clinical application of Web Accessible Population Pharmacokinetic Service™ Hemophilia (WAPPS® Hemo): Patterns of blood sampling and patient characteristics among clinician users. <i>Haemophilia</i> , 2020, 26, 56-63.	1.0	7
22	A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S52-S62.	1.0	18
23	A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. <i>Thrombosis Research</i> , 2020, 196, 550-558.	0.8	2
24	Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models. <i>Maternal and Child Nutrition</i> , 2020, 16, e12938.	1.4	27
25	Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS® Hemo project. <i>Haemophilia</i> , 2020, 26, 384-400.	1.0	26
26	Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2019, 82, 789-814.	1.1	15
27	Open Systems Pharmacology Community™ An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 878-882.	1.3	58
28	A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. <i>Thrombosis Research</i> , 2019, 184, 31-37.	0.8	3
29	Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 368-376.	1.8	22
30	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 528-541.	1.0	18
31	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 427-438.	0.8	8
32	Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 411-426.	0.8	25
33	Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 500-510.	1.3	13
34	Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1085-1096.	1.9	34
35	Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation. <i>Pharmaceutics</i> , 2019, 11, 179.	2.0	35
36	Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1603-1611.	1.6	25

#	ARTICLE	IF	CITATIONS
37	Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S73-S85.	1.0	12
38	Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 585-599.	1.5	48
39	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 535-548.	1.0	50
40	Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on <sc>ECMO</sc>. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 629-637.	1.3	29
41	Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 277-290.	0.8	24
42	What is the role for population pharmacokinetics in hemophilia?. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 125-136.	0.5	7
43	Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 814-822.	1.3	10
44	Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. <i>Pharmaceutical Research</i> , 2017, 34, 2579-2595.	1.7	30
45	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. <i>Pharmaceutics</i> , 2017, 9, 47.	2.0	17
46	Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. <i>Veterinary Anaesthesia and Analgesia</i> , 2016, 43, 35-43.	0.3	3
47	The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1313-1321.	1.5	44
48	Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility. <i>Pharmaceutical Research</i> , 2016, 33, 52-71.	1.7	48
49	Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol. <i>JMIR Research Protocols</i> , 2016, 5, e239.	0.5	86
50	Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). <i>JMIR Research Protocols</i> , 2016, 5, e232.	0.5	43
51	Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. <i>Cancer Research</i> , 2015, 75, 2478-2488.	0.4	136
52	Parameterization of small intestinal water volume using PBPK modeling. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 67, 55-64.	1.9	6
53	A Blended Learning Approach to Teaching Basic Pharmacokinetics and the Significance of Face-to-Face Interaction. <i>American Journal of Pharmaceutical Education</i> , 2010, 74, 88.	0.7	63
54	Physiology-Based Simulations of a Pathological Condition. <i>Clinical Pharmacokinetics</i> , 2008, 47, 743-752.	1.6	144

#	ARTICLE	IF	CITATIONS
55	Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 401-431.	0.8	199
56	A Mechanistic Approach for the Scaling of Clearance in Children. <i>Clinical Pharmacokinetics</i> , 2006, 45, 683-704.	1.6	186
57	Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1013-1034.	1.6	288
58	A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	1.9	3